Table 2 Relationships between p14 ARF promoter methylation and clinicopathological data, p53 and MDM2 protein expression, TP53 mutational status, and microsatellite instability phenotype
Clinicopathological and molecular parameters | Overall (%) | p14 ARF promoter methylation profile | ||
|---|---|---|---|---|
Unmethylated | Dense or partial methylation | P value | ||
Age, years, mean ± SD | 64 ± 12 | 69 ± 10 | 0.20571 | |
Gender | ||||
Male | 16 (46%) | 5 (45.5%) | 11 (45.8%) | 0.9833 |
Female | 19 (54%) | 6 (54.5%) | 13 (54.2%) | |
Type of tissue | ||||
Tumor | 35 | 11 (31%) | 24 (69%) | 0.0019 |
Adjacent colon mucosa | 35 | 24 (69%) | 11 (31%) | |
Tumor location | ||||
Right side | 10 (29%) | 3 (27.3%) | 7 (29.2%) | >0.05 |
Left side | 25 (71%) | 8 (72.7%) | 17 (70.8%) | |
Differentiation | ||||
Well or moderate | 22 (62.9%) | 10 (90.9%) | 12 (50%) | 0.0270 |
Poor or mucinous | 13 (37.1%) | 1 (9.1%) | 12 (50%) | |
Clinical stage | ||||
Stage I | 3 (8.6%) | - | 3 (12.5%) | 0.46742 |
Stage II | 17 (48.6%) | 5 (45.4%) | 12 (50%) | |
Stage III | 9 (25.7%) | 3 (27.3%) | 6 (25%) | |
Stage IV | 6 (17.1%) | 3 (27.3%) | 3 (12.5%) | |
p53 immunohistochemistry | ||||
Negative pattern | 5 (14.3%) | 3 (27.3%) | 2 (8.3%) | 0.02752 |
Diffuse pattern | 13 (37.1%) | 6 (54.5%) | 7 (29.2%) | |
Restricted overexpression | 17 (48.6%) | 2 (18.2%) | 15 (62.5%) | |
MDM2 immunohistochemistry | ||||
Negative | 12 (34.3%) | 7 (63.6%) | 5 (20.8%) | 0.0223 |
Overexpression | 23 (65.7%) | 4 (36.4%) | 19 (79.2%) | |
p21 immunohistochemistry | ||||
Loss to mild | 9 (25.7%) | 6 (54.5) | 3 (12.5%) | 0.01462 |
Moderate to high | 26 (74.3%) | 5 (45.5) | 21 (87.5%) | |
TP53 mutational status | ||||
Mutation present | 10 (28.6%) | 5 (45.5%) | 5 (20.8%) | 0.2266 |
No mutation detected | 25 (71.4%) | 6 (54.5%) | 19 (79.2%) | |
MSI status | ||||
MSI-H | 11 (31.4%) | 1 (9.1%) | 10 (41.7%) | 0.0539 |
MSS | 24 (68.6%) | 10 (90.9%) | 14 (58.3%) | |